Cellectar Biosciences is entering a strategic partnership with City of Hope Cancer Center, one of the largest cancer research and treatment organizations in the United States, the organization announced recently.

“City of Hope is a world-renowned cancer research center with extensive clinical expertise,” Cellectar Senior Vice President – Medical Dr. Andrei Shustov said in a statement. “This collaboration further substantiates iopofosine as a potential treatment for a wide variety of cancers.”

According to a release, the collaboration will focus on the clinical development of Cellectar’s lead radioconjugate asset, iopofosine I 131, in mycosis fungoides (MF), a rare form of non-Hodgkin’s lymphoma (NHL) that affects the skin and, in some patients, internal organs and blood.

As previously reported, the biotech company is preparing to submit a New Drug Application (NDA) to the FDA on its CLOVER WaM pivotal study in WM in the second half of 2024.